La Crosse Method Protocol
Why Are Allergy Drops Not FDA Approved?
Updated 8 minutes

FDA approval belongs to a specific product and its labeled uses—not to every treatment made from the same ingredients. Certain sublingual immunotherapy (SLIT) tablets are FDA-approved. Patient-specific compounded allergy drops are not FDA-approved final products, and using injectable allergenic extracts under the tongue is off-label.
Three treatments, different approval boundaries
“Allergy immunotherapy” describes a treatment approach. A tablet, an injectable extract and a patient-specific bottle of drops are products or preparations used in that approach. Calling drops a therapy rather than a product does not explain their regulatory status.
| Treatment | What approval covers | What it does not establish |
|---|---|---|
SLIT tablets | Specific FDA-approved products for their labeled allergens, ages and indications, administered under the tongue. | Approval of a tablet does not approve a compounded liquid, a different mixture, or another treatment protocol. |
Injectable allergenic extracts | FDA-approved/licensed products for the diagnostic skin-testing and/or injection immunotherapy uses specified in each label. | Licensure for skin testing or subcutaneous injection is not approval for oral use or for every final mixture made from those extracts. |
Patient-specific allergy drops | Aqueous or glycerinated preparations may use licensed allergenic extracts prescribed for off-label sublingual use. | The final compounded drop formulation is not FDA-approved. Approval of its extract ingredients does not establish FDA evaluation of the final formulation, oral route, safety or effectiveness. |
Approval is not simply a “one allergen only” rule. ORALAIR contains pollens from five grass species; ODACTRA contains extracts from two house dust mite species. FDA also labels a short-and-giant-ragweed injectable extract mixture for specified diagnostic and injection uses. These examples do not authorize every multi-allergen preparation. There is no basis here for predicting that FDA will “never” approve a future drop product. Sources 1–5.
Which SLIT tablets are FDA-approved?
The following product-specific labels describe treatment of allergen-induced allergic rhinitis, with or without conjunctivitis, confirmed by the relevant positive skin test or allergen-specific IgE testing. Each label—not a general age claim about all immunotherapy—sets its own eligibility requirements.
| Product | Labeled allergen indication | Labeled ages | Label source |
|---|---|---|---|
ODACTRA | House dust mite: Dermatophagoides farinae or D. pteronyssinus. | 5 through 65 years | |
GRASTEK | Timothy grass or cross-reactive grass pollens. | 5 through 65 years | |
RAGWITEK | Short ragweed pollen. | 5 through 65 years | |
ORALAIR | Sweet vernal, orchard, perennial rye, Timothy and Kentucky blue grass pollens; testing positive to any of those five species. | 5 through 65 years |
These are inhalant-allergy indications, not food-allergy indications or immediate symptom-relief treatments. The ORALAIR FDA-hosted file retains a draft header; its age and allergen indication should be read alongside the current submitted label, not treated as a new 2026 approval.
Approval does not mean risk-free
All four tablet labels carry a boxed warning for severe allergic reactions, including potentially life-threatening anaphylaxis and serious throat/upper-airway reactions. They require the first dose in a healthcare setting under experienced clinical supervision and observation for at least 30 minutes. They also require prescribed epinephrine and training in its use. These safeguards describe the tablets' labels; they are not instructions for starting or dosing drops.
The labels contraindicate use in people with severe, unstable or uncontrolled asthma, a history of severe systemic allergic reactions or severe local reactions to SLIT, or eosinophilic esophagitis, among other product-specific restrictions. A clinician must evaluate the full label and the person's medical history. A label's age range alone is not a determination that a patient is eligible. Sources 1–4.
What does off-label mean for allergy drops?
FDA explains that clinicians generally may prescribe an approved drug for an unapproved use when medically appropriate. A different route of administration can be off-label: an extract labeled for skin testing or injection is not labeled for administration under the tongue.
Off-label use by itself does not prove danger, and it does not prove the safety or effectiveness of any particular mixture. FDA has not determined safety and effectiveness for that unapproved use. A licensed starting extract is not the same as FDA approval of the final oral preparation. A patient-specific prescription and clinical judgment do not change that approval boundary. FDA's off-label explanation.
Compounding rules are not product approval
Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act provide limited exemptions for certain compounded drugs when their conditions are met. Section 503A generally addresses patient-specific compounding; section 503B addresses registered outsourcing facilities and includes current good manufacturing practice requirements. Neither framework is an FDA approval of a finished compounded product. Registration is not proof that a particular preparation is safe, effective or of verified quality.
There is an additional boundary for allergenic extracts: they are biological products. FDA states that biological products are not eligible for the compounded-drug exemptions under 503A or 503B. Its January 2018 guidance describes a conditional enforcement policy for certain activities involving licensed biological products. The allergenic-extract section is specifically about prescription sets for subcutaneous immunotherapy; it should not be described as an approval or blanket legal authorization for oral allergy drops.
What does the evidence support—and where does it stop?
Evidence must match the allergen, route, formulation, protocol and patient population being considered. Tablet trials evaluate standardized tablet products; their findings cannot automatically validate a different liquid formulation or a custom multi-allergen mixture.
A 2013 systematic review by Lin and colleagues examined aqueous SLIT in randomized trials for allergic rhinoconjunctivitis and asthma. It found moderate overall evidence supporting effectiveness, while identifying a need for higher-quality studies of optimal dosing and limitations in adverse-event reporting. Its findings are not a demonstration that every patient-specific mixture is effective or free of serious risk. Its historical statement about the absence of U.S. SLIT approval predates the tablet approvals and is not current tablet status.
The 2024 Clinical Practice Guideline: Immunotherapy for Inhalant Allergy distinguishes subcutaneous immunotherapy, SLIT tablets and aqueous SLIT, including their regulatory differences. It calls for education about risks, benefits, convenience and costs; selection of clinically relevant allergens; and assessment of asthma and other contraindications. It does not establish approval or universal safety for compounded drops. Its scope is inhalant allergy, not personalized food-allergy treatment. Sources 9–10.
What to discuss with an allergy specialist
An allergy specialist should connect your symptoms and testing to clinically relevant allergens and compare appropriate options, including medicines, avoidance measures and immunotherapy. Ask what evidence applies to the proposed formulation, what is off-label, who prepares it, how quality is assessed, and what supervision and emergency plan are needed.
Anaphylaxis history, asthma control, pregnancy, eosinophilic esophagitis, medicines that affect emergency treatment, and a child's age require specific evaluation. The 2024 guideline advises against initiating immunotherapy during pregnancy, with uncontrolled asthma, or when injectable epinephrine cannot be tolerated. Young children and people with food or drug allergy need an in-person specialist assessment rather than extrapolation from this inhalant-allergy explainer. Breathing difficulty or signs of a severe allergic reaction warrant immediate emergency care.
Common questions
Are allergy drops FDA-approved because the extracts are approved?
No. An extract's licensed diagnostic or injection use does not approve a final compounded oral drop formulation. Product, route and formulation are separate approval questions.
Does off-label mean unsafe?
Not by itself. It also does not establish safety or effectiveness. The clinician must evaluate evidence and risks for the specific product, formulation, protocol and patient.
Can tablets treat more than one allergen species?
Yes. ORALAIR includes five grass species and ODACTRA includes two house dust mite species. Their approvals are still product-specific, not approval of arbitrary mixtures.
Does a 503B registration make compounded drops FDA-approved?
No. Outsourcing-facility registration is not product approval or proof of a particular preparation's quality. Biological products also do not qualify for the 503A/503B compounded-drug exemptions.
Sources
- FDA: ODACTRA prescribing information—June 2026 revision; sections 1, 2, 4 and boxed warning.
- FDA: GRASTEK prescribing information—March 2022 revision; sections 1, 2, 4 and boxed warning.
- FDA: RAGWITEK prescribing information—March 2022 revision; sections 1, 2, 4 and boxed warning.
- FDA: ORALAIR prescribing information and FDA product record; DailyMed submitted label—June 2025 revision. The FDA-hosted document carries a draft header and November 2018 indication change.
- FDA: Short Ragweed and Short and Giant Ragweed Pollen Mix Allergenic Extract prescribing information—labeled percutaneous/intradermal diagnostic uses and subcutaneous immunotherapy, not oral administration.
- FDA: Understanding unapproved use of approved drugs (off-label)—clinical prescribing and the limits of FDA's evaluation.
- FDA: Compounding and FDA questions and answers—approval, quality standards, oversight and biological-product limits.
- FDA: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application—January 2018 nonbinding guidance, sections II.C and III.C; subcutaneous prescription-set policy is not an oral-drop approval.
- Gurgel et al., Clinical Practice Guideline: Immunotherapy for Inhalant Allergy (2024)—inhalant-allergy scope, candidacy, contraindications and discussion of immunotherapy modalities.
- Lin et al., JAMA (2013), systematic review of aqueous SLIT—doi:10.1001/jama.2013.2049; route-specific evidence with dosing and adverse-event-reporting limitations.
Find a provider for an individual evaluation or request information from Allergychoices.
